Clinical Trials
3 trialsNCT07570173 2026-05-26
MK-1045-005
Merck Sharp & Dohme LLC
Phase 2/3 Recruiting
NCT04660799 2023-10-12
A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)
Hoffmann-La Roche
Phase 2 Completed
NCT02999633 2022-03-21
ISLAY
Sanofi
Phase 2 Terminated